ArticleThe Journal of investigative dermatology2003
The heregulin/human epidermal growth factor receptor as a new growth factor system in melanoma with multiple ways of deregulation.
Article in The Journal of investigative dermatology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 47 citations in OpenAlex.
- Emerging Roles for Browning of White Adipose Tissue in Prostate Cancer Malignant Behaviour.International journal of molecular sciences · 2021Review
- Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies.PloS one · 2011Article
- V3 versican isoform alters the behavior of human melanoma cells by interfering with CD44/ErbB-dependent signaling.The Journal of biological chemistry · 2011Article
- The fibroblast-derived paracrine factor neuregulin-1 has a novel role in regulating the constitutive color and melanocyte function in human skin.Journal of cell science · 2010Article
- Embryonic requirements for ErbB signaling in neural crest development and adult pigment pattern formation.Development (Cambridge, England) · 2008Article
- The ERBB3 receptor in cancer and cancer gene therapy.Cancer gene therapy · 2008Review
- ESTDAB: a collection of immunologically characterised melanoma cell lines and searchable databank.Cancer immunology, immunotherapy : CII · 2006Article
- Endogenous neuregulin restores radial glia in a (ferret) model of cortical dysplasia.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2005Article
- Listeria monocytogenes produces a pro-invasive factor that signals via ErbB2/ErbB3 heterodimers.Journal of cancer research and clinical oncology · 2005Article
- Melanoma cells secrete follistatin, an antagonist of activin-mediated growth inhibition.Oncogene · 2004Article
- Roles for neuregulins in human cancer.Clinical & experimental metastasis · 2004Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In a screening for new growth factors released by melanoma cells, we found that the p185-phosphorylating capacity of a medium conditioned by a melanoma cell line was due to the secretion of heregulin, a ligand for the human epidermal growth factor receptor (HER) family of receptor tyrosine kinases. Expression of heregulin, including a new isoform, and secretion of functionally active protein was found in several cell lines. Receptor activation by heregulin, either autocrine or paracrine, resulted in a potent growth stimulation of both melanocytes and melanoma cells. Heregulin receptor HER3 and coreceptor HER2 were the main receptors expressed by these cells. Nevertheless, none of the cell lines in our panel overexpressed HER2 or HER3. In contrast, loss of HER3 was found in two cell lines, whereas one cell line showed loss of functional HER2, both types of deregulations resulting in unresponsiveness to heregulin. This implies the heregulin/HER system as a possible important physiologic growth regulatory system in melanocytes in which multiple deregulations may occur during progression toward melanoma, all resulting in, or indicating, growth factor independence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.